The monoclonal antibodies (mAbs), daratumumab and elotuzumab, targeting CD38 and SLAMF7, respectively, were the first approved immunotherapies for MM in 2015 [23,24,25,26,27,28,29]. Here, CD38 is linked to Miyoshi myopathy.